Bloodletter of Aclazotz

Updated 2026-05-06

Bloodletter of Aclazotz is grinding higher on steady accumulation, up +10.1% over thirty days with no pullback conviction. The foil mythic has climbed from its nineteen-day trough of $37.36 to trade at $41.07, a +9.9% recovery that sits just 0.2% below its recent peak of $41.14, suggesting overhead resistance is minimal and buyers are meeting offers consistently. The seven-day reading of +0.7% shows deceleration from the month-long momentum, which tracks expected behavior after a ten-point sprint. What matters now is whether this card holds $40 as a floor or reverts to the $38 zone, since the absence of sharp pullbacks typically precedes either a breakout or a fatigue flush. Watch for liquidity depth at current levels; if market depth is thin, the next buyer flush could test higher, but supply overhang from set release remains a structural headwind worth monitoring.